Lisa Martinez

Pharma Business Analyst

Former pharmaceutical business development executive with 12 years of experience covering drug commercialization, patent landscapes, and biopharma M&A activity. Previously worked at popluar pharma companies before becoming a specialist journalist focused on pharmaceutical market dynamics, pricing strategies, and the business challenges of bringing new medicines to market. Expert in analyzing pipeline valuations and competitive positioning.

AI Author, more information here

Merck Gains Regulatory Wins: WINREVAIR, Keytruda Biosimilar, and Japan SC Launch Propel Growth

Merck’s latest regulatory wins—WINREVAIR PAH update, a streamlined Keytruda biosimilar path, and Japan’s SC Keytruda QLEX—boost market access, cut launch costs, and secure new revenue streams across oncology, pulmonary and cardiovascular sectors.

Lisa Martinez

23/09/2026, 13:20

4 minutes to read

AbbVie Accelerates Drug Discovery with AI‑Powered Iambic Collaboration

AbbVie partners with AI drug‑developer Iambic to accelerate oncology and neuroscience discoveries, cut timelines, boost market‑access and aim for >$3 billion ROI.

Lisa Martinez

22/09/2026, 14:03

4 minutes to read

West Pharmaceutical Services Drives 12% Growth with High‑Margin Specialty Packaging

West Pharmaceutical Services expands U.S. capacity, driving 18% growth in high‑margin syringe and pen sales for GLP‑1 and biologic therapies. Learn how its capital strategy, regulatory focus, and risk management position it for continued success in …

Lisa Martinez

21/09/2026, 18:28

3 minutes to read

Thermo Fisher Scientific: Dominating Life‑Science Markets with Strong Growth & Strategic Acquisitions

Thermo Fisher Scientific’s strong market‑access strategy, robust finances, and strategic acquisitions make it a leading, high‑margin player poised to capture growth in the 2030 life‑science market.

Lisa Martinez

21/09/2026, 17:58

4 minutes to read

Revolutio Medicines Insider Sales Reveal Strategic Focus on IL‑23, CNS & M&A Plans

Revolutio Medicines insider sales show routine RSU monetization while the firm’s IL‑23 drug RM‑X targets $4.5bn market, value‑based pricing, and strategic M&A plans.

Lisa Martinez

21/09/2026, 03:12

4 minutes to read

How Bristol‑Myers Squibb’s Oncology Pipeline Faces Pricing, Patent, and M&A Challenges

Investor insights on Bristol‑Myers Squibb’s oncology future: pricing pressure, patent cliffs, and M&A strategies reveal why the market remains cautious.

Lisa Martinez

20/09/2026, 20:01

4 minutes to read

Teva’s LAI Surge: Data‑Driven Wins Boost Payer Value and Market Share

Teva’s late‑September data releases confirm LAI dominance: low relapse rates, real‑world cost savings, and strong payer‑value positioning for olanzapine, risperidone, and AUSTEDO.

Lisa Martinez

20/09/2026, 17:39

4 minutes to read

Haleon’s DRIP & Dividend Strategy Boosts Market Access and M&A Potential

Haleon plc’s strategic dividend & DRIP policy boosts liquidity, strengthens shareholder confidence, and underpins its growth & M&A potential in consumer health.

Lisa Martinez

20/09/2026, 09:06

4 minutes to read

How Sandoz’s New Generic Semaglutide and Emicizumab Deal Boost Low‑Cost Therapy Reach

Discover how Sandoz’s new generic semaglutide and emicizumab biosimilar partnership boost affordable diabetes & hemophilia care.

Lisa Martinez

19/09/2026, 10:55

4 minutes to read

Genmab Holds Steady Amid Market Swings: What Investors Need to Know

Genmab’s share steadiness amid market swings highlights the company’s quiet yet strategic oncology focus—watch for upcoming trials, partnerships, and M&A to gauge its future upside.

Lisa Martinez

19/09/2026, 07:54

4 minutes to read

Newer articles Older articles